Management Team
Michael Chaparian, PhD
CEO & Chief Scientific Officer.
Over 18 years of biotech and drug discovery experience. Formerly President & CSO of
OmniScience Pharmaceuticals, President of Blue Planet Technologies,
and Director of Biotechnology Development at Arizona State
University.
Donald Anderson, MD
Head of Clinical Development and Regulatory Affairs. Over
25 years ID clinical development experience. Formerly CSO of
The Upjohn Company, Pharmacia/Upjohn, VP Pharmacogenomics for
Anventis Pharmaceuticals.
Andrew Slee, PhD
Head
of Microbiology and Preclinical Pharmacology. Over 25 years of
preclinical development experience. Formerly Sr. Director Preclinical Pharmacology,
Anti-infectives, Safety Pharmacology, and Cardiovascular Sciences,
Dupont Pharma and Dupont Merck Pharma; VP of Pharmacology, Enanta
Pharmaceuticals.
Rick Lundberg
Head of Business Development. Over 20 years experience in
platform and therapeutic partnering and business development,
alliances, and M&A (formerly Director
of BD at Targanta, Senior Manager of BD at Celera)
Janette Kowalik, MBA
Head of Finance and Administration. Over 20 years experience in
finance, treasury management, human resources and facilities
management. Formerly Vice President at Comerica Bank, Director
of Finance and Administration at OmniScience Pharmaceuticals.
Advisors and Consultants
George Drusano, MD
-
Co-Director, Emerging Infections and Pharmacodynamics Laboratory, Albany Medical College
-
Co-Director and Senior Staff Scientist, Ordway Research
Institute
-
Director, Clinical Pharmacology Studies Unit, Albany Medical
College
-
Research Physician, Wadsworth Center, NYS Dept. of Health
Gary
Zurenko, MS
-
Over 30 years experience in preclinical development and
pharmacology of antimicrobials
-
Currently
CSO of Micromyx
-
Formerly with Upjohn, Upjohn/Pharmacia; discovery and reg.
filing team for Zyvox™, Vantin™, Cleocin™
Dean
Shinabarger, PhD
-
Over 18 years of experience in antimicrobial discovery and
development
-
Currently CEO of Micromyx
-
Formerly Procter & Gamble Pharma and Pharmacia; Zyvox™
development and marketing team
Arny Demain, PhD
-
Fellow, Charles A. Dana Research
Institute, Drew University
-
Founder and former Head of Fermentation Microbiology at Merck & Co.
-
Former Professor of Industrial
Microbiology Department, MIT
-
Member of the National Academy of
Sciences
Board of Directors
Jens Eckstein, PhD
General Partner, TVM Capital
Ashok Dhanrajgir
Partner and Sr. Vice President, Inventages Venture Capital
Michael Chaparian, PhD
CEO and Chief Scientific Officer, SelectX Pharmaceuticals
Claude Nash, PhD
Independent Director. Formerly Chairman & CEO, Viropharma; VP for Infectious Disease and
Oncology at Schering Plough Research Institute; and Head of
Infectious Disease at SmithKline Beecham. |
SelectX Pharmaceuticals, Inc.
One Innovation Drive
Worcester, MA 01605
Phone: (508) 798-0216
Fax: (508) 798-0217
info@selectxpharm.com |
